(2R,13R,14S,15S,17S)-17-hydroxy-2,13,14,15-tetramethyl-14-propanoyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one

• ChemBase ID: 772
• Molecular Formular: C24H34O3
• Molecular Mass: 370.52496
• Monoisotopic Mass: 370.25079495
• SMILES: O[C@@H]1C2C(C3[C@@]([C@@]([C@@H](C3)C)(C)C(=O)CC)(C1)C)CCC1=CC(=O)C=C[C@]21C
• Canonical SMILES: CCC(=O)[C@@]1(C)[C@H](C)CC2[C@]1(C)C[C@H](O)C1C2CCC2=CC(=O)C=C[C@]12C
• InChI: InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17?,18?,19+,21?,22+,23+,24-/m1/s1
• InChIKey: QTTRZHGPGKRAFB-PAIWTFDUSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (2R,13R,14S,15S,17S)-17-hydroxy-2,13,14,15-tetramethyl-14-propanoyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
• IUPAC Traditional name: rimexolone
• Brand Name: Vexol
• Synonyms: Rimexolone

Database IDs

• CAS Number: 49697-38-3
• PubChem SID: 160964235; 46504820
• PubChem CID: 39507

CALCULATED PROPERTIES

JChem

• Acid pKa: 18.761986
• H Acceptors: 3
• H Donor: 1
• LogD (pH = 5.5): 4.381233
• LogD (pH = 7.4): 4.3812323
• Log P: 4.3812323
• Molar Refractivity: 109.0676 cm^3
• Polarizability: 42.29908 Å^3
• Polar Surface Area: 54.37 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 3.64
• LOG S: -4.48
• Solubility (Water): 1.21e-02 g/l

PROPERTIES

Physical Property

• Solubility: Insoluble
• Hydrophobicity(logP): 4.2

DETAILS

DrugBank - DB00896

• Drug Groups: approved
• Description: Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol
• Indication: For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
• Pharmacology: Rimexolone is a glucocorticoid corticosteroid for systemic use. Corticosteroids suppress the inflammatory response to a variety of inciting agents of a mechanical, chemical, or immunological nature. They inhibit edema, cellular infiltration, capillary dilatation, fibroblastic proliferation, deposition of collagen and scar formation associated with inflammation.
• Toxicity: Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.
• Affected Organisms: Humans and other mammals
• Biotransformation: Undergoes extensive metabolism. Following intravenous administration of radiolabeled rimexolone in rats, more than 80% of the dose was excreted in the feces as rimexolone and metabolites. Metabolites have been shown to be either less active than rimexolone or inactive in human glucocorticoid receptor binding assays.
• Absorption: Systemically absorbed.
• Half Life: The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).
• Elimination: Following IV administration of radio-labelled rimexolone to rats, greater than 80% of the dose is excreted via the feces as rimexolone and metabolites.
• External Links: Wikipedia; RxList; Drugs.com